AstraZeneca Lifts Forecast, Buyback Amid Brilinta Win
AstraZeneca Plc raised its earnings forecast for the third time this year and doubled a share buyback plan as the anti-clot drug Brilinta moved one step closer to approval and a U.S. court upheld a patent on the Crestor cholesterol medicine.
Read more on BusinessWeek
UPDATE 2-AstraZeneca doubles buyback as Brilinta shines
Read more on FOX Business
Related posts:
- AstraZeneca weighs options after Canadian Court decision on Nexium
- AstraZeneca weighs options after Canadian Court decision on Nexium
- Latest “prilosec” News
- AstraZeneca weighs options after Canadian Court decision on Nexium
- Latest Prilosec News